Bethany Pitcher

2.1k total citations
27 papers, 832 citations indexed

About

Bethany Pitcher is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Bethany Pitcher has authored 27 papers receiving a total of 832 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Bethany Pitcher's work include Lung Cancer Treatments and Mutations (11 papers), Colorectal Cancer Treatments and Studies (8 papers) and Melanoma and MAPK Pathways (8 papers). Bethany Pitcher is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Colorectal Cancer Treatments and Studies (8 papers) and Melanoma and MAPK Pathways (8 papers). Bethany Pitcher collaborates with scholars based in Canada, United States and France. Bethany Pitcher's co-authors include Melania Pintilie, Ming‐Sound Tsao, Suzanne Kamel‐Reid, Geoffrey Liu, Igor Puzanov, David M. Hyman, Noopur Raje, José Baselga, Jean‐Yves Blay and Ian Chau and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Bethany Pitcher

27 papers receiving 815 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bethany Pitcher Canada 16 516 402 337 237 104 27 832
Jia Luo United States 15 528 1.0× 458 1.1× 328 1.0× 288 1.2× 108 1.0× 64 1.0k
Elisabetta Pietri Italy 15 593 1.1× 200 0.5× 320 0.9× 364 1.5× 78 0.8× 27 909
Guochun Zhang China 19 572 1.1× 478 1.2× 456 1.4× 525 2.2× 117 1.1× 62 1.1k
Simon Peter Gampenrieder Austria 15 654 1.3× 245 0.6× 247 0.7× 318 1.3× 55 0.5× 56 937
Tejas Patil United States 16 544 1.1× 624 1.6× 228 0.7× 161 0.7× 62 0.6× 67 836
Fangchao Zheng China 9 425 0.8× 278 0.7× 272 0.8× 203 0.9× 51 0.5× 33 800
Klaus Uwe Gruetzner Germany 8 527 1.0× 407 1.0× 180 0.5× 240 1.0× 35 0.3× 8 911
Xuezhi Hao China 21 733 1.4× 690 1.7× 372 1.1× 216 0.9× 70 0.7× 114 1.1k
Yunjiang Liu China 13 517 1.0× 235 0.6× 186 0.6× 188 0.8× 29 0.3× 57 813
Tamara Shenkier Canada 9 523 1.0× 207 0.5× 337 1.0× 325 1.4× 89 0.9× 12 816

Countries citing papers authored by Bethany Pitcher

Since Specialization
Citations

This map shows the geographic impact of Bethany Pitcher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bethany Pitcher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bethany Pitcher more than expected).

Fields of papers citing papers by Bethany Pitcher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bethany Pitcher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bethany Pitcher. The network helps show where Bethany Pitcher may publish in the future.

Co-authorship network of co-authors of Bethany Pitcher

This figure shows the co-authorship network connecting the top 25 collaborators of Bethany Pitcher. A scholar is included among the top collaborators of Bethany Pitcher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bethany Pitcher. Bethany Pitcher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Drilon, Alexander, Chao‐Hua Chiu, Yun Fan, et al.. (2022). Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC. JTO Clinical and Research Reports. 3(6). 100332–100332. 72 indexed citations
2.
Bazhenova, Lyudmila, Stephen V. Liu, W. Marston Linehan, et al.. (2021). 533P Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours. Annals of Oncology. 32. S598–S599. 4 indexed citations
3.
Subbiah, Vivek, Igor Puzanov, Jean‐Yves Blay, et al.. (2020). Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers. Cancer Discovery. 10(5). 657–663. 86 indexed citations
4.
Dziadziuszko, Rafał, Salvatore Siena, Daniel S.W. Tan, et al.. (2020). 1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline. Annals of Oncology. 31. S833–S834. 5 indexed citations
5.
Krebs, Matthew, Filippo de Braud, Salvatore Siena, et al.. (2020). 1287P Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis. Annals of Oncology. 31. S831–S833. 3 indexed citations
6.
Gogas, Helen, Brigitte Dréno, James Larkin, et al.. (2020). Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Annals of Oncology. 32(3). 384–394. 71 indexed citations
7.
Subbiah, Vivek, Radj Gervais, Gregory J. Riely, et al.. (2019). Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology. 1–9. 57 indexed citations
8.
9.
Ottolino‐Perry, Kathryn, Kristina M. Blackmore, Liis Lindvere‐Teene, et al.. (2017). Improved detection of clinically relevant wound bacteria using autofluorescence image‐guided sampling in diabetic foot ulcers. International Wound Journal. 14(5). 833–841. 43 indexed citations
10.
Thompson, Robert M., Marc Potvin, Jordan A. Holmes, et al.. (2017). Hazards and incidents: Detection and learning in radiation medicine, a comparison of 2 educational interventions. Practical Radiation Oncology. 7(6). e431–e438. 3 indexed citations
11.
Pitcher, Bethany, Leila Khoja, Robert J. Hamilton, et al.. (2017). Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS). PLoS ONE. 12(2). e0170544–e0170544. 10 indexed citations
12.
Labbé, Catherine, Michael Cabanero, Grzegorz Korpanty, et al.. (2017). Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC). Lung Cancer. 111. 23–29. 154 indexed citations
13.
Hyman, David M., Thomas Kaley, Antoine Hollebecque, et al.. (2017). Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.. Journal of Clinical Oncology. 35(15_suppl). 2004–2004. 1 indexed citations
14.
Sullivan, Ryan J., René González, Karl D. Lewis, et al.. (2017). Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.. Journal of Clinical Oncology. 35(15_suppl). 3063–3063. 41 indexed citations
15.
Wu, Licun, Ghassan Allo, Thomas John, et al.. (2016). Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma. Clinical Cancer Research. 23(4). 1060–1067. 40 indexed citations
16.
17.
Pintilie, Melania, Hala Muaddi, Selim Chaib, et al.. (2016). MATE2 Expression Is Associated with Cancer Cell Response to Metformin. PLoS ONE. 11(12). e0165214–e0165214. 29 indexed citations
18.
Labbé, Catherine, Grzegorz Korpanty, Pascale Tomasini, et al.. (2016). Prognostic and predictive effects of TP53 mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 34(15_suppl). 11585–11585. 6 indexed citations
19.
Lohse, Ines, Ramya Kumareswaran, Pinjiang Cao, et al.. (2016). Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts. PLoS ONE. 11(12). e0167272–e0167272. 22 indexed citations
20.
Mackay, Helen, Bethany Pitcher, Amit M. Oza, et al.. (2016). Prospective evaluation of quality of life (QOL) during a phase I/II study of adjuvant chemotherapy with image-guided high-precision radiotherapy for completely resected gastric cancer.. Journal of Clinical Oncology. 34(4_suppl). 164–164. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jia Luo Breakdown of academic impact, for papers by Elisabetta Pietri Breakdown of academic impact, for papers by Guochun Zhang Breakdown of academic impact, for papers by Simon Peter Gampenrieder Breakdown of academic impact, for papers by Tejas Patil Breakdown of academic impact, for papers by Fangchao Zheng Breakdown of academic impact, for papers by Klaus Uwe Gruetzner Breakdown of academic impact, for papers by Xuezhi Hao Breakdown of academic impact, for papers by Yunjiang Liu Breakdown of academic impact, for papers by Tamara Shenkier
Rankless by CCL
2026